Will BRIC small-caps prevail in 2013?
Wrapping up 2012 it’s worthwhile comparing the performance of four emerging market small cap exchange traded funds with a diversified BRIC ETF.
Tag Archives: HAO
China stocks fall but investors should stand up and take note
Investors in Chinese stocks cannot get a break as the mainland index falls to its lowest level in four years and normally defensive consumer-staple companies fall the most in three years.
Time to buy China ETFs?
Billions of investment dollars have started flowing back into China recently. Indications are that the Chinese economy is stabilizing and that investors are becoming concerned they might miss the recovery. Challenges persist however and the short term future is uncertain.
Is it time to get back into China investments?
Jim O’Neill, Chairman of Goldman Sachs Asset Management and the legend behind the BRIC acronym (Brazil, Russia, India and China), made headlines this week proclaiming the time to get back into China investments is now.
Has the Chinese economy averted a hard landing already?
A report issued August 10 by Barclay’s economists Jian Chang, Yiping Huang, and Steven Lingxiu Yang suggests the slowdown in the Chinese economy may be over and that growth will accelerate during the remainder of 2012.
Three emerging market ETFs at risk of extinction
Just as new emerging market ETFs can be created, so they can be eliminated. One very important trading and investing consideration is liquidity. Can you find a seller for your shares when you need to, or are you stuck with shares you can’t sell?
There is a liquidity problem for many Chinese ETFs
Size isn’t everything, but there are limits to how small traders are willing to get in pursuit of market-beating performance — especially in notoriously volatile emerging markets.
What you need to know about exotic Chinese ETFs
A casual survey of the ETF marketplace reveals 17 separate exchange-traded products that concentrate on Chinese stocks. Many promise exposure to theoretically exciting investment themes, but for most, realizing that promise still carries significant risk.
Chinese rail capacity hurting coal profits
U.S. China Mining Group (SGZH, quote) reported solid profits of $7 million on $54 million in sales today. The Chinese coal mining company brought up concerns about China’s railway system, however, noting that some sales decisions were based on who could move the coal instead of who could pay the most for it.
Sihuan Pharmaceutical develops first anti-hypertensive drug
Leading Chinese pharmaceutical company Sihuan Pharmaceutical announced March 11 that its application to register Tylerdipine Hydrochloride has been accepted by the Chinese State Food and Drug Administration. The new drug is the first anti-hypertensive developed by Sihuan Pharmaceutical’s in-house research and development team.
